MacroGenics

NASDAQ: MGNX ↗ $4.13 USD ~$140M MCAP

#HER2-Positive Breast Cancer #Solid Tumors #Hematologic Malignancies #Bispecific Antibody Therapy #Antibody-Drug Conjugates (ADCs)

MacroGenics is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapeutics for cancer. Its proprietary DART and TRIDENT bispecific platforms enable multi-specific targeting, and the company has one approved HER2-targeted breast cancer drug, Margenza (margetuximab-cmkb).

Company Info

Sector: Biotechnology / Oncology

Headquarters: Rockville, Maryland, USA

Founded: 2000

Website: macrogenics.com/

Upcoming Milestones & Key Dates

Q2 2026

Clinical Trial

Margenza U.S. sales update and additional HER2 breast cancer clinical data

Q3 2026

Clinical Trial

Lorigerlimab Phase 2 LINNET study clinical update in ovarian cancer

Clinical Development Pipeline

Margenza (margetuximab-cmkb)

Target: HER2 (Fc-engineered to enhance ADCC)

Third-line metastatic HER2-positive breast cancer (in combination with chemo)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

MGC026

Target: B7-H3 antibody-drug conjugate (exatecan payload)

Advanced Solid Tumors (B7-H3 expressing)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Lorigerlimab

Target: PD-1 × CTLA-4 bispecific checkpoint inhibitor

Platinum-Resistant Ovarian and Clear Cell Gynecologic Cancers

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Scott Koenig, M.D., Ph.D.

President and Chief Executive Officer

Jim Karrels

Senior Vice President, Chief Financial Officer

Ezio Bonvini, Ph.D.

Senior Vice President, Research and Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →